References
- GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden or disease study 2017. Lancet. 2019;4:934–947.
- Rahib L, Wehner MR, Matrisian LM, et al. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708.
- Afshar N, English DR, Milne RL. Factors explaining socio-economic inequalities in cancer survival: a systematic review. Cancer Control. 2021;28:10732748211011956.
- Fonseca AL, Kahn H, Mehari KR, et al. Disparities in access to oncologic care in pancreatic cancer: a systematic review. Ann Surg Oncol. 2022. DOI:https://doi.org/10.1245/s10434-021-11258-6
- Anthes LE, Hajizadeh M. Socioeconomic inequalities in pancreatic cancer incidence in Canada: evidence from cancer registry data. J Publ Health. 2020.
- Cirera L, Huerta JM, Chirlaque MD, et al. Socioeconomic effect of education on pancreatic cancer risk in Western Europe: an update on the EPIC cohorts study. Cancer Epidemiol Biomarkers Prev. 2019;28(6):1089–1092.
- Pastrana del Valle J, Fillmore NR, Molina G. Socioeconomic disparities in pancreas cancer resection and surgical in the veterans health administration. Ann Surg Oncol. 2022. DOI:https://doi.org/10.1245/s10434-022-11384-9
- Thobie A, Mulliri A, Bouvier V, et al. Same chance of accessing resection? Impact of socioeconomic status on resection rates among patients with pancreatic Adenocarcinoma-A Systematic Review. Health Equity. 2021;5(1):143–150.
- Fonseca AL, Cherla D, Kothari AN, et al. Association of Medicaid expansion with pancreatic cancer treatment and outcomes: evidence from the national cancer database. Ann Surg Oncol. 2022;29(1):342–351.
- Sanford NN, Aguilera TA, Folkert MR, et al. Chemotherapy among patients with resected stage I-III pancreatic adenocarcinoma. JNCCN. 2019;17:1292–1300.
- Mora J, Krepline AN, Aldakkak M, et al. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high area deprivation index neighborhoods. Am J Surg. 2021;222(1):10–17.
- Hamad A, DePuccio M, Reames BN, et al. Disparities in stage-specific guideline-concordant cancer.directed treatment for patients with pancreatic adenocarcinoma. J Gastrointest Surg. 2021;25(11):2889–2901.
- Ladekarl M, Rasmussen LS, Kirkegård J, et al. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Acta Oncol. 2021. DOI:https://doi.org/10.1080/0284186X.2021.2012252
- Chu QD, Hsieh MC, Gibbs JF, et al. Treatment at a high-volume academic research program mitigates racial disparities in pancreatic adenocarcinoma. J Gastrointest Oncol. 2021;12(6):2579–2590.
- Hue JJ, Katayama ES, Markt SC, et al. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Surgery. 2021. DOI:https://doi.org/10.1016/j.surg.2021.10.023